-
Hapoalim Maintains Neutral on Whole Foods Market (WFMI)
Monday, May 2, 2011 - 8:45am | 100Read More...Hapoalim is out with its report today on Whole Foods Market (NASDAQ: WFMI), maintaining Neutral. In a note to clients, Hapoalim writes, "We maintain our Neutral rating and $60 PT. Even with our above consensus estimates for FY11, investors are likely going to require an implied two-year ID sales...
-
Hapoalim Maintains Sell on First Solar (FSLR)
Wednesday, April 27, 2011 - 7:48am | 203Read More...Hapoalim is out with its report today on First Solar (NASDAQ: FSLR), maintaining Sell. In a note to clients, Hapaolim writes, "Heading into FSLR's 1Q11 earnings report next Tuesday, May 3, 2011, we are lowering our FY11 estimates to levels we believe properly account for the impact policy...
-
Hapoalim Comments on Italy's Solar Subsidy 'Overhaul' (FSLR, SPWRA)
Wednesday, April 20, 2011 - 8:46am | 262Read More...Hapoalim is out with its report today on Italy's decision to "overhaul" its solar subsidy program. In a note to clients, Hapoalim writes, "Though subject to change, Italy's draft legislation to overhaul its solar subsidy program sheds light on Italy's impact on 2H11/2012 industry demand and...
-
Hapoalim Upgrades LLY From Hold To Buy, Raises PT To $39
Tuesday, April 19, 2011 - 8:34am | 95Read More...Hapoalim is upgrading shares of Eli Lilly & Co. (NYSE: LLY) from Hold to Buy. “We are also increasing our Price Target to $39,” Hapoalim writes. “As a result of better-than-expected 1Q sales, we are increasing our 2011-2014 revenue estimates. Additionally as a result of higher than expected...
-
Hapoalim Reiterates Sell Rating On MNKD
Monday, April 11, 2011 - 7:16am | 141Read More...Hapoalim Securities is reiterating its Sell rating on shares of MannKind Corp. (NASDAQ: MNKD). “MannKind announced that due to a potential government shutdown, the FDA has decided to cancel an Afrezza End-of-Review meeting scheduled for April 15,” Hapoalim writes. “We note that other FDA...
-
Hapoalim Reiterates Neutral on Nash Finch Company (NAFC)
Friday, March 4, 2011 - 9:07am | 144Read More...Hapoalim is out with its report on Nash Finch Company (NASDAQ: NAFC), reiterating Neutral. In a note to clients, Hapoalim writes, "NAFC executed at a very high level in 4Q10, with a reported 6.3% improvement in adjusted EBITDA. While we think it's premature to call an inflection point and assume...
-
Hapoalim Lowers PT on Nektar Therapeutics to $17 (NKTR)
Wednesday, March 2, 2011 - 8:28am | 122Read More...Hapoalim is out with its report on Nektar Therapeutics (NASDAQ: NKTR), lowering its price target from $19 to $17. In a note sent to clients, Hapoalim writes, "Nektar is moving slowly on the planning of its Phase 3 program for NKTR-102 in breast and ovarian cancer, implying 2012 will now be the year...
-
Hapoalim Maintains Sell on First Solar (FSLR)
Tuesday, February 22, 2011 - 8:19am | 109Read More...Hapoalim is out with its report today on First Solar (NASDAQ: FSLR), maintaining Sell and a $110 price target. In a note to clients, Hapoalim writes, "In light of FSLR's shifting business focus away from strictly technology/manufacturing towards energy delivery and project development, we believe a...
-
Hapoalim Reiterates Sell on MannKind (MNKD)
Friday, February 11, 2011 - 10:05am | 131Read More...Hapoalim is out with its report on Mannkind (NASDAQ: MNKD), reiterating Sell. In a note to clients, Hapoalim writes, "MannKind announced that it will wait for FDA input before beginning the AFFINITY trials. If we assume that MannKind meets with the FDA in April 2011, gets back official feedback in...
-
Hapoalim Maintains Sell on Energy Conversion Devices (ENER)
Thursday, February 10, 2011 - 11:22am | 128Read More...Hapoalim is out with its report today on Energy Conversion Devices (NASDAQ: ENER), maintaining Sell. In a note to clients, Hapoalim writes, "While ENER reported a FY2Q11 EPS loss of ($0.16), x‐1x items EPS of ($0.26) was relatively in line with the Street at ($0.27). Most importantly, consistent...
-
Hapoalim Reiterates Buy on Alkermes (ALKS)
Friday, February 4, 2011 - 10:54am | 125Read More...Hapoalim is out with its report today on Alkermes (NASDAQ: ALKS), reiterating Buy and a $16 price target. In a note to clients, Hapoalim writes, "Last night, Alkermes reported fiscal 3Q11 earnings of ($0.12), which was $0.04 above our and the consensus estimate. Total revenues were $0.4 million...
-
Hapoalim Reiterates Hold on Eli Lilly (LLY)
Friday, January 28, 2011 - 9:46am | 115Read More...Hapoalim is out with its report today on Eli Lilly (NYSE: LLY), reiterating Hold after reporting in-line 2011 guidance. In a note to clients, Hapoalim writes, "The company forecasted 2011 continuing EPS in the range of $4.15 to $4.30, which contains our previous 2011 EPS estimate of $4.26. At $35....
-
Hapoalim Upgrades SVU To Buy
Wednesday, December 22, 2010 - 7:04am | 47Read More...Analysts at Hapoalim upgrade Supervalu Inc (NYSE: SVU) from “hold” to “buy.” The target price for SVU is set to $10. SVU shares gained 1.49% to close at $8.85 yesterday. More Analyst Ratings here
-
Targacept Hosts Analyst Day (TRGT)
Friday, December 3, 2010 - 8:06am | 119Read More...Hapoalim is out with its research report today on Targacept (NASDAQ: TRGT) following TRGT's analyst day. In a note to clients, Hapoalim writes, "Targacept hosted an Analyst Day yesterday, highlighting inflammation and Parkinson's disease as its next focus areas. In addition to the new therapeutic...
-
Earnings Preview: Hapoalim Previews STP Earnings
Tuesday, November 16, 2010 - 8:46am | 82Read More...Looking ahead to Suntech Power Holdings' (NYSE: STP) 3Q10 earnings report on Wednesday morning, November 17, 2010, Hapoalim reaffirms its forecast for 3Q10 EPS of $0.21, slightly below consensus of $0.23. “Though we foresee no surprises in the quarter, we continue to believe STP's high‐cost...
